Research programme: seasonal influenza nanoparticle vaccine - Novavax

Drug Profile

Research programme: seasonal influenza nanoparticle vaccine - Novavax

Alternative Names: Influenza nanoparticle vaccine - Novavax; NanoFlu vaccine - Novavax

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novavax
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 08 Aug 2017 Immunogenicity data from a preclinical trial in Influenza virus infections (Prevention) released by Novavax
  • 08 Aug 2017 Novavax plans a phase I/II trial for Influenza viral infections (Prevention)
  • 02 Jun 2016 Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top